Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

References

• Siegel JE, Clancy CM. Using economic evaluations in decision making. In: Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation (2nd Edition). Haddix AC, Teutsch SM, Corso PS (Eds). Oxford University Press, London, UK 178–198 (2003).
   Google Scholar
• Garber AM. Cost–effectiveness and evidence evaluation as criteria for coverage policy. Health Aff. (Millwood)W4, 284–296 (2004).
   Google Scholar
• Neumann PJ. Using Cost–Eeffectiveness Analysis to Improve Health Care. Oxford University Press, NY, USA (2005).
   Google Scholar
• Chapman RH, Berger M, Weinstein MC, Weeks JC, Goldie S, Neumann PJ. When does quality-adjusting life-years matter in cost–effectiveness analysis? Health Econ.13, 4299–436 (2004).
   Google Scholar
• Tengs TO. Cost–effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health7, 70–78 (2004).
   PubMed Web of Science ®Google Scholar
• Weinstein MC. High-priced technology can be good value for money. Ann. Intern. Med.130, 857–858 (1999).
   PubMedGoogle Scholar
• Weinstein MC. From cost–effectiveness ratios to resource allocation: where to draw the line? In: Valuing Health Care. Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. Sloan FA (Ed.). Cambridge University Press, NY, USA, 77–97 (1995).
   Google Scholar
• Detsky AS. Economics and cost–effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear. Am. Heart J.137, S51–S52 (1999).
   PubMed Web of Science ®Google Scholar
• Weinstein MC. Decision rules for incremental cost–effectiveness analysis. In: The Elgar Companion to Health Economics. Jones AM (Ed.). Elgar, Cheltenham, UK, 470–479 (2006).
   Google Scholar
• Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. J. Public Econ.2, 147–157 (1973).
   Google Scholar
• Detsky AS, Naglie IG. A clinician’s guide to cost–effectiveness analysis. Ann. Intern. Med.113, 147–154 (1990).
   PubMed Web of Science ®Google Scholar
• Drummond M, Torrance G, Mason J. Cost–effectiveness league tables: more harm than good? Soc. Sci. Med.37, 33–40 (1993).
   PubMed Web of Science ®Google Scholar
• Birch S, Gafni A. Cost–effectiveness ratios: in a league of their own. Health Policy28, 133–141 (1994).
   PubMed Web of Science ®Google Scholar
• Goldman L, Garber AM, Grover SA, Hlatky MA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 6 . Cost effectiveness of assessment and management of risk factors. J. Am. Coll. Cardiol.27, 1020–1030 (1996).
   PubMed Web of Science ®Google Scholar
• Mauskopf J, Rutten F, Schonfeld W. Cost–effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics21, 991–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Gafni A, Birch S. Incremental cost–effectiveness ratios (ICERs): the silence of the lambda. Soc. Sci. Med.62, 2091–2100 (2006).
   PubMed Web of Science ®Google Scholar
• Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost–effectiveness threshold. J. Health Serv. Res. Policy11, 46–51 (2006).
   PubMedGoogle Scholar
• Birch S, Gafni A. Decision rules in economic evaluation. In: The Elgar Companion to Health Economics. Jones AM (Ed.). Elgar, Cheltenham, UK, 492–502 (2006).
   Google Scholar
• Dolan R, Edlin R. Is it really possible to build a bridge between cost–benefit analysis and cost–effectiveness analysis? J. Health Econ.21, 827–843 (2002).
   PubMedGoogle Scholar
• Hammitt JK. QALYs versus WTP. Risk Anal.22, 985–1001 (2002).
   PubMed Web of Science ®Google Scholar
• Klose T. A utility-theoretic model for QALYs and willingness to pay. Health Econ.12, 17–31 (2003).
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen D. Willingness to pay for a QALY: theoretical and methodological issues. Pharmacoeconomics23, 423–432 (2005).
   PubMed Web of Science ®Google Scholar
• Smith RD, Richardson J. Can we estimate the ‘social’ value of a QALY? Four core issues to resolve. Health Policy74, 77–84 (2005).
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Valuing Health for Regulatory Cost–Effectiveness Analysis. Miller W, Robinson LA, Lawrence RS (Eds). National Academies Press, DC, USA (2006).
   Google Scholar
• O’Brien BJ, Gertsen K, Willan AR, Faulkner LA. Is there a kink in consumers’ threshold value for cost–effectiveness in health care? Health Econ.11, 175–180 (2002).
   PubMed Web of Science ®Google Scholar
• Corso PS, Hammitt JK, Graham JD, Dicker RC, Goldie SJ. Assessing preferences for prevention versus treatment using willingness to pay. Med. Decis. Making22, S92–S101 (2002).
   PubMed Web of Science ®Google Scholar
• Franic DM, Pathak DS, Gafni A. Quality-adjusted life years was a poor predictor of women’s willingness to pay in acute and chronic conditions: results of a survey. J. Clin. Epidemiol.58, 291–303 (2005).
   PubMed Web of Science ®Google Scholar
• Van Houtven G, Powers J, Jessup A, Yang JC. Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP? Health Econ.15, 775–795 (2006).
   PubMed Web of Science ®Google Scholar
• Gyrd-Hansen D. Willingness to pay for a QALY. Health Econ.12, 1049–1060 (2003).
   PubMed Web of Science ®Google Scholar
• Byrne MM, O’Malley K, Suarez-Almazor ME. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis. Med. Decis. Making25, 655–666 (2005).
   PubMed Web of Science ®Google Scholar
• King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med. Decis. Making25, 667–677 (2005).
   PubMed Web of Science ®Google Scholar
• Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psych.1, 61–80 (1982).
   Google Scholar
• Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? CMAJ146, 473–481 (1992).
   PubMed Web of Science ®Google Scholar
• Owens DK. Analytic tools for public health decision making. Med. Decis. Making22, S3–S10 (2002).
   PubMedGoogle Scholar
• Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manag. Sci.7, 43–49 (2004).
   PubMedGoogle Scholar
• Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch. Intern. Med.163, 1637–1641 (2003).
   PubMed Web of Science ®Google Scholar
• Briggs AH, O’Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost–effectiveness studies. Annu. Rev. Public Health23, 377–401 (2002).
   PubMed Web of Science ®Google Scholar
• Groot Koerkamp B, Hunink MG, Stijnen T, Hammitt JK, Kuntz KM, Weinstein MC. Limitations of acceptability curves for presenting uncertainty in cost–effectiveness analysis. Med. Decis. Making27(2), 101–111 (2007).
   PubMed Web of Science ®Google Scholar
• Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost–effectiveness analysis. Med. Decis. Making18, S68–S80 (1998).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost–effective? A review of the evidence. Health Aff. (Millwood)19, 92–109 (2000).
   PubMed Web of Science ®Google Scholar
• Greenberg D, Winkelmayer WC, Neumann PJ. Prevailing judgments about society’s willingness to pay for a QALY: do they vary by country? Have they changed over time? Abstr. Value Health9, A-60 (2006).
   Google Scholar
• Garber AM, Phelps CE. Economic foundations of cost–effectiveness analysis. J. Health Econ.16, 1–31 (1997).
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer D, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Presented at: Academy Health’s Annual Research Meeting. Orlando, FL, USA, 5 June, 2007.
   Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med. Decis. Making20, 332–342 (2000).
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost–effectiveness analysis in health-care resource allocation decision-making: how are cost–effectiveness thresholds expected to emerge? Value Health7, 518–528 (2004).
   PubMed Web of Science ®Google Scholar
• Su X, Zenios SA, Chertow GM. Incorporating recipient choice in kidney transplantation. J. Am. Soc. Nephrol.15, 1656–1663 (2004).
   PubMedGoogle Scholar
• Gillick MR. Medicare coverage for technological innovations – time for new criteria? N. Engl. J. Med.350, 2199–2203 (2004).
   PubMedGoogle Scholar
• Laufer F. Thresholds in cost–effectiveness analysis – more of the story. Value Health8, 86–87 (2005).
   PubMed Web of Science ®Google Scholar
• Garner TI, Dardis R. Cost–effectiveness analysis of end-stage renal disease treatments. Med. Care25, 25–34 (1987).
   PubMed Web of Science ®Google Scholar
• Winkelmayer WC, Weinstein MC, Mittleman MA, Glynn RJ, Pliskin JS. Health economic evaluations: the special case of end-stage renal disease treatment. Med. Decis. Making22, 417–430 (2002).
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures in economic evaluation in health care. Annu. Rev. Public Health21, 587–611 (2000).
   PubMed Web of Science ®Google Scholar
• Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J. Chronic Dis.31, 697–704 (1978).
   PubMedGoogle Scholar
• Churchill DN, Torrance GW, Taylor DW et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin. Invest. Med.10, 14–20 (1987).
   PubMed Web of Science ®Google Scholar
• Hornberger JC, Redelmeier DA, Petersen J. Variability among methods to assess patients’ well-being and consequent effect on a cost–effectiveness analysis. J. Clin. Epidemiol.45, 505–512 (1992).
   PubMed Web of Science ®Google Scholar
• Laupacis A, Keown P, Pus N et al. A study of the quality of life and cost–utility of renal transplantation. Kidney Int.50, 235–242 (1996).
   PubMed Web of Science ®Google Scholar
• Torrance GW, Zipursky A. Cost–effectiveness of antepartum prevention of Rh immunization. Clin. Perinatol.11, 267–281 (1984).
   PubMed Web of Science ®Google Scholar
• Torrance GW. Measurement of health state utilities for economic appraisal. J. Health Econ.5, 1–30 (1986).
   PubMed Web of Science ®Google Scholar
• Churchill DN, Lemon BC, Torrance GW. Cost–effectiveness analysis comparing continuous ambulatory peritoneal dialysis to hospital hemodialysis. Med. Decis. Making4, 489–500 (1984).
   Google Scholar
• Quinn RR. Naimark DM, Oliver MJ, Bayoumi AM. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost–utility analysis. Am. J. Kidney Dis.50, 421–432 (2007).
   PubMed Web of Science ®Google Scholar
• Tsevat J. Impact and cost–effectiveness of smoking interventions. Am. J. Med.93, 43S–47S (1992).
   PubMed Web of Science ®Google Scholar
• Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann. Intern. Med.114, 798–802 (1991).
   PubMed Web of Science ®Google Scholar
• Krahn M, Detsky AS. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost–effectiveness analysis. Med. Decis. Making13, 4–20 (1993).
   PubMed Web of Science ®Google Scholar
• Smith TE, Hillner BE. The efficacy and cost–effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J. Clin. Oncol.11, 771–776 (1993).
   PubMed Web of Science ®Google Scholar
• Smith TE, Hillner BE, Desch CE. Efficacy and cost–effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J. Natl. Cancer Inst.85, 1460–1474 (1993).
   PubMed Web of Science ®Google Scholar
• Mark DB, Hlatky MA, Califf RM et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N. Engl. J. Med.332, 1418–1424 (1995).
   PubMed Web of Science ®Google Scholar
• Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost–effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA265, 1145–1151 (1991).
   PubMed Web of Science ®Google Scholar
• McCarthy BD, Wong JB, Munoz A, Sonnenberg FA. Who should be screened for HIV infection? A cost–effectiveness analysis. Arch. Intern. Med.153, 1107–1116 (1993).
   PubMedGoogle Scholar
• Owens DK, Harris RA, Scott PM, Nease RF Jr. Screening surgeons for HIV infection: a cost–effectiveness analysis. Ann. Intern. Med.122, 641–652 (1995).
   PubMedGoogle Scholar
• Morrison A, Glassberg H. Determinants of the cost–effectiveness of statins. J. Manag. Care Pharm.9, 544–551 (2003).
   PubMedGoogle Scholar
• Tosteson AN, Goldman L, Udvarhelyi IS, Lee TH. Cost–effectiveness of a coronary care unit versus an intermediate care unit for emergency department patients with chest pain. Circulation94, 143–150 (1996).
   PubMed Web of Science ®Google Scholar
• Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM. Cost–effectiveness of screening for carotid stenosis in asymptomatic persons. Ann. Intern. Med.126, 337–346 (1997).
   PubMed Web of Science ®Google Scholar
• Hamel MB, Phillips RS, Davis RB et al. Outcomes and cost–effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. Ann. Intern. Med.127, 195–202 (1997).
   PubMed Web of Science ®Google Scholar
• Hillner BE, McLeod DG, Crawford ED, Bennett CL. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology45, 633–640 (1995).
   PubMedGoogle Scholar
• Mark DB. Medical economics in cardiovascular medicine. In: Textbook of Cardiovascular Medicine. Topol EJ (Ed.). Lippincott-Raven, NY, USA, 1033–1062 (1997).
   Google Scholar
• Mark DB, Harrington RA, Lincoff AM et al. Cost–effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation101, 366–371 (2000).
   PubMed Web of Science ®Google Scholar
• Hayman J, Weeks J, Mauch P. Economic analyses in health care: an introduction to the methodology with an emphasis on radiation therapy. Int.J. Radiat. Oncol. Biol. Phys.35, 827–841 (1996).
   PubMed Web of Science ®Google Scholar
• Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA272, 773–780 (1994).
   PubMed Web of Science ®Google Scholar
• Nichol G, Laupacis A, Stiell IG et al. Cost–effectiveness analysis of potential improvements to emergency medical services for victims of out-of-hospital cardiac arrest. Ann. Emerg. Med.27, 711–720 (1996).
   PubMed Web of Science ®Google Scholar
• Tsevat J, Duke D, Goldman L et al. Cost–effectiveness of captopril therapy after myocardial infarction. J. Am. Coll. Cardiol.26, 914–919 (1995).
   PubMed Web of Science ®Google Scholar
• Kent KC, Kuntz KM, Patel MR et al. Perioperative imaging strategies for carotid endarterectomy. An analysis of morbidity and cost–effectiveness in symptomatic patients. JAMA274, 888–893 (1995).
   PubMedGoogle Scholar
• Fiscella K, Franks P. Cost–effectiveness of the transdermal nicotine patch as an adjunct to physicians’ smoking cessation counseling. JAMA275, 1247–1251 (1996).
   PubMed Web of Science ®Google Scholar
• Goldman L, Gordon DJ, Rifkind BM et al. Cost and health implications of cholesterol lowering. Circulation85, 1960–1968 (1992).
   PubMed Web of Science ®Google Scholar
• Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost–effectiveness analysis in heart disease, Part III: ischemia, congestive heart failure, and arrhythmias. Prog. Cardiovasc. Dis.37, 307–346 (1995).
   PubMedGoogle Scholar
• Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost–effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer77, 1854–1861 (1996).
   PubMed Web of Science ®Google Scholar
• Earle CC, Chapman RH, Baker CS et al. Systematic overview of cost–utility assessments in oncology. J. Clin. Oncol.18, 3302–3317 (2000).
   PubMed Web of Science ®Google Scholar
• Ramsey SD. Economic analyses and clinical practice guidelines: why not a match made in heaven? J. Gen. Intern. Med.17, 235–237 (2002).
   PubMed Web of Science ®Google Scholar
• Freedberg KA, Tosteson AN, Cotton DJ, Goldman L. Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost–effective analysis. J. Gen. Intern. Med.7, 261–272 (1992).
   PubMedGoogle Scholar
• Kinosian BP, Eisenberg JM. Cutting into cholesterol. Cost–effective alternatives for treating hypercholesterolemia. JAMA259, 2249–2254 (1988).
   PubMed Web of Science ®Google Scholar
• Eddy DM. Screening for breast cancer. Ann. Intern. Med.111, 389–399 (1989).
   PubMed Web of Science ®Google Scholar
• Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost–effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA263, 407–413 (1990).
   PubMed Web of Science ®Google Scholar
• Owens DK, Nease RF, Harris R. Use of cost–effectiveness and value of information analyses to customize guidelines for specific clinical practice settings. Med. Decis. Making13, 395 (1993) (Abstract).
   Google Scholar
• Holtgrave DR, Qualls NL. Threshold analysis and programs for prevention of HIV infection. Med. Decis. Making15, 311–317 (1995).
   PubMed Web of Science ®Google Scholar
• Holtgrave DR, Qualls NL, Graham JD. Economic evaluation of HIV prevention programs. Annu. Rev. Public Health17, 467–488 (1996).
   PubMed Web of Science ®Google Scholar
• Patrick DL, Erickson P. DL, Erickson P. Health Status and Health Policy: Quality of Life in Health Care Evaluation and Resource Allocation. Oxford University Press, NY, USA, 27–57 (1993).
   Google Scholar
• Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost–effectiveness of routine coronary angiography after acute myocardial infarction. Circulation94, 957–965 (1996).
   PubMed Web of Science ®Google Scholar
• Manns BJ, Taub KJ, Donaldson C. Economic evaluation and end-stage renal disease: from basics to bedside. Am. J. Kidney Dis.36, 12–28 (2000).
   PubMedGoogle Scholar
• Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost–effectiveness analysis. J. Pediatr.136, 201–208 (2000).
   PubMed Web of Science ®Google Scholar
• Ubel PA, Nord E, Gold M, Menzel P, Prades JL, Richardson J. Improving value measurement in cost–effectiveness analysis. Med. Care38, 892–901 (2000).
   PubMed Web of Science ®Google Scholar
• Owens DK. Interpretation of cost–effectiveness analyses. J. Gen. Intern. Med.13, 716–717 (1998).
   PubMed Web of Science ®Google Scholar
• Nichol KL. Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults. Vaccine17, S67–S73 (1999).
   PubMedGoogle Scholar
• Sanders GD, Nease RF Jr, Owens DK. Publishing web-based guidelines using interactive decision models. J. Eval. Clin. Pract.7, 175–189 (2001).
   PubMedGoogle Scholar
• van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang.83, 146–155 (2002).
   PubMed Web of Science ®Google Scholar
• Azimi NA, Welch HG. The effectiveness of cost–effectiveness analysis in containing costs. J. Gen. Intern. Med.13, 664–669 (1998).
   PubMed Web of Science ®Google Scholar
• Chang RW, Pellisier JM, Hazen GB. A cost–effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA275, 858–865 (1996).
   PubMed Web of Science ®Google Scholar
• Mushlin AI, Mooney C, Holloway RG, Detsky AS, Mattson DH, Phelps CE. The cost–effectiveness of magnetic resonance imaging for patients with equivocal neurological symptoms. Int. J. Technol. Assess. Health Care13, 21–34 (1997).
   PubMedGoogle Scholar
• Freedberg KA, Scharfstein JA, Seagle GR III et al. The cost–effectiveness of preventing AIDS-related opportunistic infections. JAMA279, 130–136 (1998).
   PubMed Web of Science ®Google Scholar
• Hayman JA, Hillner BE, Harris JR, Weeks JC. Cost–effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J. Clin. Oncol.16, 1022–1029 (1998).
   PubMed Web of Science ®Google Scholar
• Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C: risks, benefits,and costs. JAMA280, 2088–2093 (1998).
   PubMed Web of Science ®Google Scholar
• Kallmes DF, Kallmes MH. Cost–effectiveness of angiography performed during surgery for ruptured intracranial aneurysms. AJNR Am. J. Neuroradiol.18, 1453–1462 (1997).
   PubMed Web of Science ®Google Scholar
• Smith KJ, Roberts MS. Cost effectiveness of newer antiviral agents for herpes zoster: is the evidence spotty? J. Infect. Dis.178, S85–S90 (1998).
   PubMedGoogle Scholar
• Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost–effectiveness of a universal, school-based hepatitis B vaccination program. Am. J. Public Health88, 1638–1644 (1998).
   PubMed Web of Science ®Google Scholar
• Ashenfelter O. Measuring the value of a statistical life: problems and prospects. Econ. J.116, C10–C23 (2006).
   Google Scholar
• Rosen AB, Cutler DM, Norton DM, Hu HM, Vijan S. The value of coronary heart disease care for the elderly: 1987–2002. Health Aff. (Millwood)26, 111–123 (2007).
   PubMedGoogle Scholar
• Braithwaite RS, Roberts MS. $50,000 per QALY: inertia, indifference, or irrationality? Presented at: Annual Meeting of the Society for Medical Decision Making. Atlanta, GA, USA, 17–20 October, 2004.
   Google Scholar
• Goldman L. Cost–effectiveness in a flat world – can ICDs help the United States get rhythm? N. Engl. J. Med.353, 1513–1515 (2005).
   PubMedGoogle Scholar
• Fox-Rushby J, Mills A, Walker D. Setting health priorities: the development of cost–effectiveness league tables. Bull. World Health Organ.79, 679–680 (2001).
   PubMedGoogle Scholar
• Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost–effectivenessanalysis. N. Engl. J. Med.353, 1516–1522 (2005).
   PubMed Web of Science ®Google Scholar
• Nord E. Cost–Value Analysis in Health Care: Making Sense out of QALYs. Cambridge University Press, Cambridge, UK (1999).
   Google Scholar
• Nord E, Pinto JL, Richardson J, Menzel P, Ubel P. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ.8, 25–39 (1999).
   PubMed Web of Science ®Google Scholar
• Oliver A. Prioritizing health care: is ‘health’ always an appropriate maximand? Med. Decis. Making24, 272–280 (2004).
   PubMed Web of Science ®Google Scholar
• Dolan P, Shaw R, Tsuchiya A, Williams A. QALY maximisation and people’s preferences: a methodological review of the literature. Health Econ.14, 197–208 (2005).
   PubMed Web of Science ®Google Scholar
• Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics24, 1133–1142(2006).
   PubMed Web of Science ®Google Scholar
• Nord E. Health state values from multiattribute utility instruments need correction. Ann. Med.33, 371–374(2001).
   PubMed Web of Science ®Google Scholar
• Olsen JA, Donaldson C. Helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes. Soc. Sci. Med.46, 1–12 (1998).
   PubMed Web of Science ®Google Scholar
• Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann. Allergy Asthma Immunol.80, 189–194 (1998).
   PubMedGoogle Scholar
• Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O’Brien B. valuing outcomes in health care: a comparison of willingness to pay and quality adjusted life years. J. Clin. Epidemiol.51, 667–676 (1998).
   PubMed Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds.). Cost–Effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
   Google Scholar
• Siegel JE, Weinstein MC, Torrance GW. Reporting cost–effectiveness studies and results. In: Cost–Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA, 276–303 (1996).
   Google Scholar
• Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC. The cost–effectiveness of air bags by seating position. JAMA278, 1418–1425 (1997).
   PubMed Web of Science ®Google Scholar
• Drummond MF, O’Brien B, Stoddard GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd Edition). Oxford University Press, Oxford, UK (1997).
   Google Scholar
• Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost–effectiveness of screening for cervical cancer in HIV-infected women. Ann. Intern. Med.130, 97–107 (1999).
   PubMed Web of Science ®Google Scholar
• Prosser LA, Stinnett AA, Goldman PA et al. Cost–effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann. Intern. Med.132, 769–779 (2000).
   PubMed Web of Science ®Google Scholar
• Stone PW, Teutsch S, Chapman RH, Bell C, Goldie SJ, Neumann PJ. Cost–utility analyses of clinical preventive services: published ratios, 1976–1997. Am. J. Prev. Med.19, 15–23 (2000).
   PubMed Web of Science ®Google Scholar
• George B, Harris A, Mitchell A. Cost–effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics19, 1103–1109 (2001).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Making Choices in Health: WHO Guide to Cost–effectiveness Analysis. Tan-TorresEdejer T, Baltussen R, Adam T, Hutubessy R, Acharya A (Eds). WHO Press, Geneva, Switzerland (2003).
   Google Scholar
• Hutubessy R, Chisholm D, Edejer TT. Generalized cost–effectiveness analysis for national-level priority-setting in the health sector. Cost Eff. Resour. Alloc.1, 8 (2003).
   PubMedGoogle Scholar
• Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, oh my: similarities and differences in summary measures of population health. Annu. Rev. Public Health23, 115–134 (2002).
   PubMed Web of Science ®Google Scholar
• Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan.21, 402–408 (2006).
   PubMed Web of Science ®Google Scholar
• Towse A, Pritchard C. NationalInstitute for Clinical Excellence (NICE): is economic appraisal working? Pharmacoeconomics20(Suppl. 3), 95–105 (2006).
   Google Scholar
• Dakin HA, Devlin NJ, Odeyemi IA. ‘Yes’, ‘No’ or ‘Yes, but’? Multinomial modelling of NICE decision-making. Health Policy77, 352–367 (2006).
   PubMed Web of Science ®Google Scholar
• Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. Health Technol. Assess.8(31) 1–103 (2004).
   PubMed Web of Science ®Google Scholar
• Bryan S, Williams I, McIver S. Seeing the NICE side of cost–effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. Health Econ.16, 179–193 (2007).
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost–effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ.13, 437–452 (2004).
   PubMed Web of Science ®Google Scholar
• Culyer A, McCabe C, Briggs A et al. Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. J. Health Serv. Res. Policy12, 56–58 (2007).
   PubMedGoogle Scholar
• Graham JD, Corso PS, Morris JM et al. Evaluating the cost–effectiveness of clinical and public health measures. Annu. Rev. Public Health19, 125–152 (1998).
   PubMed Web of Science ®Google Scholar
• Maciosek MV, Edwards NM, Coffield AB et al. Priorities among effective clinical preventive services: methods. Am. J. Prev. Med.31, 90–96 (2006).
   PubMed Web of Science ®Google Scholar
• Maciosek MV, Coffield AB, Edwards NM, Flottemesch TJ, Goodman MJ, Solberg LI. Priorities among effective clinical preventive services: results of a systematic review and analysis. Am. J. Prev. Med.31, 52–61 (2006).
   PubMed Web of Science ®Google Scholar
• Grosse SD, Teutsch SM, Haddix AC. Lessons from cost–effectiveness research for United States public health policy. Annu. Rev. Public Health28, 365–391 (2007).
   PubMed Web of Science ®Google Scholar
• Grosse SD, Waitzman NJ, Romano PS, Mulinare J. Reevaluating the benefits of folic acid fortification in the United States: economic analysis, regulation, and public health. Am. J. Public Health95, 1917–1922 (2005).
   PubMed Web of Science ®Google Scholar
• Marshall DA, Kleinman SH, Wong JB et al. Cost–effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang.86, 28–40 (2004).
   PubMed Web of Science ®Google Scholar
• Bell CM, Urbach DR, Ray JG et al. Bias in published cost effectiveness studies: systematic review. BMJ332, 699–703 (2006).
   PubMed Web of Science ®Google Scholar
• Martin S, Rice N, Smith PC. Further Evidence on the Link Between Health Care Spending and Health Outcomes. CHE Research Paper 32. Centre for Health Economics, University of York, York, UK (2007).
   Google Scholar
• Zarkin GA, Dean N, Mauskopf JA, Williams R. Potential health benefits of nutrition label changes. Am. J. Public Health,83, 717–724 (1993).
   PubMedGoogle Scholar
• Viscusi WK. The value of risks to life and health. J. Econ. Lit.31, 1912–1946 (1993).
   Web of Science ®Google Scholar
• Valuing Health for Policy: An Economic Approach. Tolley GS, Kenkel DS, Fabian R (Eds). University of Chicago Press, IL, USA (1994).
   Google Scholar
• Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff. (Millwood)20, 11–29 (2001).
   Google Scholar
• Robinson LA. How US government agencies value mortality risk reductions. Rev. Environ. Econ. Policy1, 283–299 (2007).
   Web of Science ®Google Scholar
• Kochi I, Hubbell B, Kramer R. An empirical Bayes approach to combining and comparing estimates of the value of a statistical life for environmental policy analysis. Environ. Resource Econ.34, 385–406 (2006).
   Web of Science ®Google Scholar
• Viscusi W, Aldy JE. The value of a statistical life: a critical review of market estimates throughout the world. J. Risk Uncertainty27, 5–76 (2003).
   Web of Science ®Google Scholar
• Krupnick A. Mortality-risk valuation and age: stated preference evidence. Rev. Environ. Econ. Policy1, 261–282 (2007).
   Web of Science ®Google Scholar
• US Department of Transportation. Revised departmental guidance: Treatment of the value of preventing fatalities and injuries in preparing economic analyses. US Department of Transportation. 5 February (2008).
   Google Scholar
• Aldy JE, Viscusi WK. Age differences in the value of statistical life: revealed preference evidence. Rev. Environ. Econ. Policy1, 241–260 (2007).
   Web of Science ®Google Scholar
• Hammitt JK. The $64,000 question: what are we willing to pay for a QALY. ISPOR Connections11(1), 7–9 (2005).
   Google Scholar
• Olsen JA, Donaldson C, Shackley P; EuroWill Group. Implicit versus explicit ranking: on inferring ordinal preferences for health care programmes based on differences in willingness-to-pay. J. Health Econ.24, 990–996 (2005).
   PubMedGoogle Scholar
• Protière C, Donaldson C, Luchini S, Moatti JP, Shackley P. The impact of information on non-health attributes on willingness to pay for multiple health care programmes. Soc. Sci. Med.58, 1257–1269 (2004).
   PubMed Web of Science ®Google Scholar
• Klarman HE, Francis JO, Rosenthal GD. Cost effectiveness analysis applied to the treatment of chronic renal disease. Med. Care6, 48–54 (1968).
   Web of Science ®Google Scholar
• Buxton MJ, West RR. Cost–benefit analysis of long-term hemodialysis for chronic renal failure. Br. Med. J.2, 376–379 (1975).
   PubMed Web of Science ®Google Scholar
• Stange PV, Sumner AT. Predicting treatment costs and life-expectancy for end-stage renal disease. N. Engl. J. Med.298, 372–378 (1978).
   PubMed Web of Science ®Google Scholar
• Roberts SD, Maxwell DR, Gross TL. Cost–effective care of endstage renal disease: a billion dollar question. Ann. Int. Med.92, 243–248 (1980).
   PubMed Web of Science ®Google Scholar
• Ludbrook A. A cost–effectiveness analysis of the treatment of chronic renal failure. Appl. Econ.13, 337–350 (1981).
   Web of Science ®Google Scholar
• Schersten T, Brynger H, Karlberg I, Jonsson E. Cost–effectiveness of organ transplantation. Int. J. Tech. Assess. Health Care,2, 545–552 (1986).
   PubMedGoogle Scholar
• Karlberg I, Nyberg G. Cost–effectiveness studies of renal transplantation. Int. J. Tech. Assess. Health Care11, 611–622 (1995).
   PubMed Web of Science ®Google Scholar
• Laupacis A, Keown P, Pus N et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int.50, 235–242 (1996).
   PubMed Web of Science ®Google Scholar
• De Vit GA, Ramsteijn PG, De Charro FT. Economic evaluation of end stage renal disease treatment. Health Policy44, 215–232 (1998).
   PubMedGoogle Scholar